While more people with HIV are receiving antiretroviral (ARV) treatment than ever before, persistent and deadly gaps in the global response to HIV/AIDS continue to undermine progress against the epidemic. In 2022, of the 39 million people living with HIV, nearly 10 million people did not receive lifesaving ARV treatment.
For more than 20 years, the MSF Access Campaign has been monitoring the patent barriers, prices and availability of ARV medicines and pushing for the uptake of policies that promote access to affordable, quality-assured treatments. The Untangling the Web report series, published from 2001-2020, was at the centre of these efforts. Since 2021, we continue to provide ARV pricing information in a condensed annual publication along with related publications focusing on key topics as needed.
